Pablo Maroto1, Camillo Porta2, Jaume Capdevila3, Andrea B Apolo4, Santiago Viteri5, Cristina Rodriguez-Antona6, Lidia Martin7, Daniel Castellano8. 1. Medical Oncology Services, Hospital de la Santa Creu i Sant Pau, Mas Casanovas, Barcelona, 08025, Spain. 2. Interdisciplinary Department of Medicine, University of Bari "Aldo Moro," Bari, Italy. 3. Department of Medical Oncology, Vall d'Hebron University Hospital, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain. 4. Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA. 5. UOMI Cancer Center, Clínica Mi Tres Torres, Barcelona, Spain. 6. National Cancer Research Center, Madrid, Spain. 7. Ipsen Pharma, Barcelona, Spain. 8. Medical Oncology Department, University Hospital 12 de Octubre, Madrid, Spain.
Abstract
Background: Cabozantinib is approved, in various settings, for the treatment of renal cell carcinoma, medullary thyroid cancer, and hepatocellular carcinoma, and it has been investigated for the treatment of other cancers. With the available evidence and the real-world performance of cabozantinib compared with clinical trial data, we performed a systematic review of cabozantinib monotherapy as treatment for solid tumors in adults. Methods: This study was designed in accordance with Preferred Reporting Items for Systematic Reviews and Meta-Analyses and registered with PROSPERO (CRD42020144680). We searched for clinical and observational studies of cabozantinib monotherapy for solid tumors using Embase, MEDLINE, and Cochrane databases (October 2020), and screened relevant congress abstracts. Eligible studies reported clinical or safety outcomes, or biomarker data. Small studies (n < 25) and studies of cabozantinib combination therapies were excluded. Quality was assessed using National Institute for Health and Care Excellence methodology, and study characteristics were described qualitatively. Results: Of 2888 citations, 114 were included (52 randomized studies, 29 observational studies, 32 nonrandomized phase I or II studies or pilot trials, and 1 analysis of data from a randomized study and a nonrandomized study). Beyond approved indications, other tumors studied were castration-resistant prostate cancer, urothelial carcinoma, Ewing sarcoma, osteosarcoma, uveal melanoma, non-small-cell lung cancer, Merkel cell carcinoma, glioblastoma, pheochromocytomas and paragangliomas, cholangiocarcinoma, gastrointestinal stromal tumor, colorectal cancer, salivary gland cancer, carcinoid and pancreatic neuroendocrine tumors, and breast, endometrial and ovarian cancers. The most common adverse events were hypertension, diarrhea, and fatigue. Conclusion: The identified evidence demonstrates the positive efficacy/effectiveness of cabozantinib monotherapy in various solid tumor types, with safety findings being consistent with those observed with other VEGFR-targeting tyrosine kinase inhibitors. When available, real-world findings were consistent with the data reported from clinical trials. A limitation of this review is the high proportion of abstracts; however, this allowed us to capture the most up-to-date findings.
Background: Cabozantinib is approved, in various settings, for the treatment of renal cell carcinoma, medullary thyroid cancer, and hepatocellular carcinoma, and it has been investigated for the treatment of other cancers. With the available evidence and the real-world performance of cabozantinib compared with clinical trial data, we performed a systematic review of cabozantinib monotherapy as treatment for solid tumors in adults. Methods: This study was designed in accordance with Preferred Reporting Items for Systematic Reviews and Meta-Analyses and registered with PROSPERO (CRD42020144680). We searched for clinical and observational studies of cabozantinib monotherapy for solid tumors using Embase, MEDLINE, and Cochrane databases (October 2020), and screened relevant congress abstracts. Eligible studies reported clinical or safety outcomes, or biomarker data. Small studies (n < 25) and studies of cabozantinib combination therapies were excluded. Quality was assessed using National Institute for Health and Care Excellence methodology, and study characteristics were described qualitatively. Results: Of 2888 citations, 114 were included (52 randomized studies, 29 observational studies, 32 nonrandomized phase I or II studies or pilot trials, and 1 analysis of data from a randomized study and a nonrandomized study). Beyond approved indications, other tumors studied were castration-resistant prostate cancer, urothelial carcinoma, Ewing sarcoma, osteosarcoma, uveal melanoma, non-small-cell lung cancer, Merkel cell carcinoma, glioblastoma, pheochromocytomas and paragangliomas, cholangiocarcinoma, gastrointestinal stromal tumor, colorectal cancer, salivary gland cancer, carcinoid and pancreatic neuroendocrine tumors, and breast, endometrial and ovarian cancers. The most common adverse events were hypertension, diarrhea, and fatigue. Conclusion: The identified evidence demonstrates the positive efficacy/effectiveness of cabozantinib monotherapy in various solid tumor types, with safety findings being consistent with those observed with other VEGFR-targeting tyrosine kinase inhibitors. When available, real-world findings were consistent with the data reported from clinical trials. A limitation of this review is the high proportion of abstracts; however, this allowed us to capture the most up-to-date findings.
Authors: Matthew Smith; Johann De Bono; Cora Sternberg; Sylvestre Le Moulec; Stéphane Oudard; Ugo De Giorgi; Michael Krainer; Andries Bergman; Wolfgang Hoelzer; Ronald De Wit; Martin Bögemann; Fred Saad; Giorgio Cruciani; Antoine Thiery-Vuillemin; Susan Feyerabend; Kurt Miller; Nadine Houédé; Syed Hussain; Elaine Lam; Jonathan Polikoff; Arnulf Stenzl; Paul Mainwaring; David Ramies; Colin Hessel; Aaron Weitzman; Karim Fizazi Journal: J Clin Oncol Date: 2016-07-11 Impact factor: 44.544
Authors: Andrea B Apolo; Rosa Nadal; Yusuke Tomita; Nicole N Davarpanah; Lisa M Cordes; Seth M Steinberg; Liang Cao; Howard L Parnes; Rene Costello; Maria J Merino; Les R Folio; Liza Lindenberg; Mark Raffeld; Jeffrey Lin; Min-Jung Lee; Sunmin Lee; Sylvia V Alarcon; Akira Yuno; Nancy A Dawson; Kimaada Allette; Arpita Roy; Dinuka De Silva; Molly M Lee; Tristan M Sissung; William D Figg; Piyush K Agarwal; John J Wright; Yangmin M Ning; James L Gulley; William L Dahut; Donald P Bottaro; Jane B Trepel Journal: Lancet Oncol Date: 2020-07-06 Impact factor: 41.316
Authors: Neesha C Dhani; Hal W Hirte; Lisa Wang; Julia V Burnier; Angela Jain; Marcus O Butler; Stephen Welch; Gini F Fleming; Jean Hurteau; Koji Matsuo; Daniela Matei; Waldo Jimenez; Carolyn Johnston; Mihaela Cristea; Katia Tonkin; Prafull Ghatage; Stephanie Lheureux; Anjali Mehta; Judy Quintos; Qian Tan; Suzanne Kamel-Reid; Olga Ludkovski; Ming-Sound Tsao; John J Wright; Amit M Oza Journal: Clin Cancer Res Date: 2020-01-28 Impact factor: 12.531
Authors: Toni K Choueiri; Sabina Signoretti; Abdallah Flaifel; Wanling Xie; David A Braun; Miriam Ficial; Ziad Bakouny; Amin H Nassar; Rebecca B Jennings; Bernard Escudier; Daniel J George; Robert J Motzer; Michael J Morris; Thomas Powles; Evelyn Wang; Ying Huang; Gordon J Freeman Journal: Clin Cancer Res Date: 2019-08-01 Impact factor: 12.531
Authors: Joel W Neal; Suzanne E Dahlberg; Heather A Wakelee; Seena C Aisner; Michaela Bowden; Ying Huang; David P Carbone; Gregory J Gerstner; Rachel E Lerner; Jerome L Rubin; Taofeek K Owonikoko; Philip J Stella; Preston D Steen; Ahmed Ali Khalid; Suresh S Ramalingam Journal: Lancet Oncol Date: 2016-11-04 Impact factor: 41.316
Authors: Robert J Motzer; Bernard Escudier; Thomas Powles; Christian Scheffold; Toni K Choueiri Journal: Br J Cancer Date: 2018-03-26 Impact factor: 7.640
Authors: Frede Donskov; Robert J Motzer; Eric Voog; Elizabeth Hovey; Carsten Grüllich; Louise M Nott; Katharine Cuff; Thierry Gil; Niels Viggo Jensen; Christine Chevreau; Sylvie Negrier; Reinhard Depenbusch; Lothar Bergmann; Izzy Cornelio; Anne Champsaur; Bernard Escudier; Sumanta Pal; Thomas Powles; Toni K Choueiri Journal: Eur J Cancer Date: 2019-12-27 Impact factor: 9.162